SEC Company Response from Oric Pharmaceuticals, Inc. (ORIC) (CIK 0001796280) (ORIC) — Apr 23, 2020
Oric Pharmaceuticals, Inc. (ORIC) (CIK 0001796280)
Date: April 23, 2020 · CIK: 0001796280 · Accession: 0001193125-20-115804
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236792
Referenced dates: April 22, 2020
Letter
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
O: 650.493.9300
F: 650.493.6811
April 23, 2020
Via EDGAR and Overnight Delivery
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Jeffrey Gabor
Ibolya Ignat
Celeste Murphy
Kevin Vaughn
Re: ORIC Pharmaceuticals, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed April 20, 2020
File No. 333-236792
Sir/Madam:
On behalf of our client, ORIC Pharmaceuticals, Inc. (“ORIC” or the “Company”), we submit this letter in response to comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) contained in its letter dated April 22, 2020, relating to the above referenced Amendment No. 1 to Registration Statement on Form S-1 (the “Registration Statement”). We are concurrently filing via EDGAR a revised Registration Statement (the “Revised Registration Statement”).
In this letter, we have recited the comments from the Staff in italicized, bold type and have followed each comment with the Company’s response. Except for page references appearing in the headings and Staff comments below (which are references to the Registration Statement), all page references herein correspond to the Revised Registration Statement.
AUSTIN BEIJING BOSTON BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO
SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE
ORIC Pharmaceuticals, Inc.
April 23, 2020
Page
Amendment No. 1 to Registration Statement on Form S-1 filed April 20, 2020
Risk Factors
Our amended and restated bylaws that will become effective upon the closing of this offering provide..., page 79
1. We note that your forum selection provision identifies a state court located within the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) as the exclusive forum for certain litigation, including any “derivative action.” Please disclose whether this provision applies to actions arising under the Exchange Act. If this provision does not apply to actions arising under the Exchange Act, please also ensure that the exclusive forum provision in the governing documents states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Exchange Act. We also note that your forum selection provision includes an exclusive federal forum provision for Securities Act claims. Please state that there is uncertainty as to whether a court would enforce such provision. In that regard, we note that Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.
In response to the Staff’s comment, the Company has updated the disclosure on pages 79 and 80 of the Revised Registration Statement. Additionally, the Company will include disclosure in future Annual Reports on Form 10-K to describe the limitations in applicability of the Company’s forum selection provision, consistent with the disclosure on pages 79 and 80.
Report of Independent Registered Public Accounting Firm, page F-2
2. Please have your auditors remove the restrictive language from their report and consent and sign them in the filing for which you request effectiveness.
In response to the Staff’s comment, the Company’s auditors have removed the restrictive language from their report and consent and signed these for inclusion in the filing for which the Company requests effectiveness.
*****
ORIC Pharmaceuticals, Inc.
April 23, 2020
Page
Please direct any questions regarding the Company’s responses or the revised draft of the Registration Statement to me at (650) 849-3223 or tjeffries@wsgr.com.
Sincerely,
WILSON SONSINI GOODRICH & ROSATI
Professional Corporation
Show Raw Text
CORRESP 1 filename1.htm CORRESP Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650.493.9300 F: 650.493.6811 April 23, 2020 Via EDGAR and Overnight Delivery U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor Ibolya Ignat Celeste Murphy Kevin Vaughn Re: ORIC Pharmaceuticals, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed April 20, 2020 File No. 333-236792 Sir/Madam: On behalf of our client, ORIC Pharmaceuticals, Inc. (“ORIC” or the “Company”), we submit this letter in response to comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) contained in its letter dated April 22, 2020, relating to the above referenced Amendment No. 1 to Registration Statement on Form S-1 (the “Registration Statement”). We are concurrently filing via EDGAR a revised Registration Statement (the “Revised Registration Statement”). In this letter, we have recited the comments from the Staff in italicized, bold type and have followed each comment with the Company’s response. Except for page references appearing in the headings and Staff comments below (which are references to the Registration Statement), all page references herein correspond to the Revised Registration Statement. AUSTIN BEIJING BOSTON BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE ORIC Pharmaceuticals, Inc. April 23, 2020 Page 2 Amendment No. 1 to Registration Statement on Form S-1 filed April 20, 2020 Risk Factors Our amended and restated bylaws that will become effective upon the closing of this offering provide..., page 79 1. We note that your forum selection provision identifies a state court located within the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) as the exclusive forum for certain litigation, including any “derivative action.” Please disclose whether this provision applies to actions arising under the Exchange Act. If this provision does not apply to actions arising under the Exchange Act, please also ensure that the exclusive forum provision in the governing documents states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Exchange Act. We also note that your forum selection provision includes an exclusive federal forum provision for Securities Act claims. Please state that there is uncertainty as to whether a court would enforce such provision. In that regard, we note that Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. In response to the Staff’s comment, the Company has updated the disclosure on pages 79 and 80 of the Revised Registration Statement. Additionally, the Company will include disclosure in future Annual Reports on Form 10-K to describe the limitations in applicability of the Company’s forum selection provision, consistent with the disclosure on pages 79 and 80. Report of Independent Registered Public Accounting Firm, page F-2 2. Please have your auditors remove the restrictive language from their report and consent and sign them in the filing for which you request effectiveness. In response to the Staff’s comment, the Company’s auditors have removed the restrictive language from their report and consent and signed these for inclusion in the filing for which the Company requests effectiveness. ***** ORIC Pharmaceuticals, Inc. April 23, 2020 Page 3 Please direct any questions regarding the Company’s responses or the revised draft of the Registration Statement to me at (650) 849-3223 or tjeffries@wsgr.com. Sincerely, WILSON SONSINI GOODRICH & ROSATI Professional Corporation /s/ Tony Jeffries Tony Jeffries cc: Jacob Chacko, ORIC Pharmaceuticals, Inc. Dominic Piscitelli, ORIC Pharmaceuticals, Inc. Kenneth Clark, Wilson Sonsini Goodrich & Rosati, P.C. Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, P.C. Melissa Rick, Wilson Sonsini Goodrich & Rosati, P.C. Charles Kim, Cooley LLP